Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer
Frank Vinluan / medcitynews - There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics. The p…
AI Summary: Oricell, a China‑based CAR‑T developer, secured fresh financing to accelerate its cell‑therapy programs and support plans to go public. The fundraising will bankroll clinical expansion, manufacturing scale‑up, and regulatory preparations as the company pushes toward broader development and an IPO ambition, positioning it to compete in the crowded CAR‑T market.
Related Stories
Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 1 month
Avalyn upsizes IPO to raise cash for lung drug trials / 2 months
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 14 days
Datroway secures regulatory approvals in breast cancer across US and EU / 7 wks
FDA flags misleading cancer drug claims tied to biotech billionaire / 3 months
TerraPower invests $450M to build Actinium‑225 radioisotope factory / 3 months
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 7 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Rural Health, Cancer Research, Eli Lilly, Healthcare and look for the RSS link.
StackHealth Time Machine